|
|
|
CONGRESS PROGRAM:
♦SUNDAY ♦ MONDAY
♦TUESDAY ♦WEDNESDAY
♦ THURSDAY♦
The 11th International Congress on Antiphospholipid Antibodies will
present new and original developments in the area of Antiphospholipid
Syndrome.Congress
Lectures and abstracts will be published in a special issue of Thrombosis
Research
that will be availible at the start of the congress.
For a PDF printable version of the congress program click
here.
For a free download of Adobe Reader click
here. 
PRECONFERENCE
WORKSHOP: SUNDAY 14TH NOVEMBER
14.25-18.10 (supported
by an unrestricted grant from the American Autoimmune Related Diseases
Associated Inc. (AARDA)
Update on the International Classification
Criteria for the Antiphospholipid Syndrome
|
14.30-14.40
Ricard Cervera
14.40-14.50
Discussion
|
CARDIAC MANIFESTATIONS
Ricard
Cervera, Yehuda Shoenfeld, Ricardo Forestiero |
|
14.50-15.00
Ware Branch
15.00-15.10
Discussion |
OBSTETRIC MANIFESTATIONS, PREGNANCY AND MORBIDITY CRITERIA
(A) PRE-ECLAMPSIA (B) HELP SYNDROME (C) INTRAUTERINE GROWTH
RETARDATION
Ware Branch,
Roger Levy, Ron Derksen
|
|
15.10-15.20
Robin Brey
15.20-15.30
Discussion
|
NEUROLOGICAL MANIFESTATIONS, STROKE (A) MIGRAINE (B) MULTIPLE
SCLEROSIS-LIKE ILLNESS (C) TRANSVERSE MYELOPATHY (D) COGNITIVE
DYSFUNCTION (E) SEIZURES
Robin Brey,
Joab Chapman, Jacob
Rand, S. Levine
|
|
15.30-15.40
Yehuda Shoenfeld
15.40-15.50
Discussion |
CUTANEOUS MANIFESTATIONS (A) LIVEDO RETICULARIS (B) CUTANEOUS
ULCERS/VASCULITIS
Yehuda
Shoenfeld,
Ricard Cervera
|
|
15.50-16.00
PierLuigi Meroni
16.00-16.10
Discussion
|
RENAL MANIFESTATIONS
PierLuigi
Meroni, Panayiotis Vlachoyiannopoulos |
|
16.10-16.20
Takao Koike
16.20-16.30
Discussion
|
THROMBOCYTOPENIA
Takao Koike,
Pierre Youinou, Benjamin
Brenner |
|
16.30-16.40
Angela
Tincani
16.40-16.50
Guido Reber
16.50-17.00
Discussion
|
DIAGNOSTIC TESTS (A) CURRENT STATUS OF IGA (B) ANTI-BETA2-GLYCOPROTEIN
I
Angela Tincani and
Guido Reber, Robert
Roubey, E Nigel Harris, Silvia Pierangeli |
|
|
|
17.00-17.10
Flip de
Groot
17.10-17.20
Ron Derksen
17.20-17.30
Discussion
|
LUPUS ANTICOAGULANT/BETA2-GPI/PROTHROMBIN/OTHER PROTEIN SPECIFICITIES
Flip de Groot,
Ron Derksen, Tom
Exner, Victoria Regnault, P. de Moerloose |
|
17.30-17.40
Takao Koike
17.40-17.50
Discussion
|
ANTIPROTHROMBIN ANTIBODIES
Takao Koike,
Monica Galli, Joyce Rauch, T. Atsumi |
|
17.50-18.00
Michael
Lockshin
18.00-18.10
Discussion
|
Summary of how well the criteria work so far and what are
the problems
Michael Lockshin
|
8.25-18.08 MONDAY NOVEMBER 15 2004
IMMUNE MEDIATED
MECHANISMS OF THROMBOSIS
CHAIRPERSONS
– SA KRILIS, T. KOIKE
|
8.25 |
Welcome
Speech
S.A. Krilis, Australia
|
|
8.30 |
B CELL
BIOLOGY, APOPTOSIS, AND AUTOANTIBODIES TO PHOSPHOLIPIDS
M. Cook, Australia
|
|
8.55 |
THE IMPACT
OF THE INFLAMMATORY RESPONSE ON COAGULATION
C. Esmon, United
States
|
|
9.20 |
INFLAMMATORY
RESPONSE AND THE ENDOTHELIUM
PL Meroni, Italy |
BETA
2-GLYCOPROTEIN I
|
9.45 |
BETA 2
GLYCOPROTEIN I -FUNCTION IN HEALTH AND DISEASE
S. Krilis,
S.
Miyakis, Australia
|
|
10.10 |
B2-GLYCOPROTEIN
I: ANTIPHOSPHOLIPID SYNDROME AND T-CELL REACTIVITY
M. Kuwana, Japan |
|
10.35
|
COFFEE
BREAK
|
ANTIPHOSPHOLIPID
SYNDROME
CHAIRPERSONS
– EN HARRIS, R. ROUBEY
|
10.50 |
PRIMARY,
SECONDARY, CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME: IS THERE
A DIFFERENCE?
EN Harris, SS Pierangeli,
United States
|
| 11.10 |
PRIMARY
ANTIPHOSPHOLIPID ANTIBODY SYNDROME AS A MODEL OF B CELL-INDUCED
AUTOIMMUNE DISEASE
P. Youinou,
France |
|
|
| 11.30 |
CELL SIGNALLING
PATHWAYS UNDERLYING PATHOGENIC AUTOIMMUNITY
M. Zouali,
France |
|
11.50 |
ANTI-PHOSPHOLIPID
ANTIBODIES AND APOPTOSIS
J. Rauch, R. Subang, JS Levine,
Canada |
|
12.10 |
ANTIBODY-MEDIATED
INTERFERENCE WITH ANNEXINS IN THE ANTIPHOSPHOLIPID SYNDROME
J. Rand, X-X Yu, United States |
| 12.30 |
MECHANISMS
OF AUTOANTIBODY- INDUCED MONOCYTE TISSUE FACTOR EXPRESSION
R. Roubey, AS Wolberg, United States |
|
12.50 LUNCH
& POSTER VIEWING
CHAIRPERSONS – J. MCINTYRE,
SS PIERANGELI, S. LEVINE |
|
13.50 |
EFFECTS
OF FLUVASTATIN ON UPREGULATION OF TISSUE FACTOR BY ANTIPHOSPHOLIPID
ANTIBODIES ON ENDOTHELIAL CELLS
SS Pierangeli,
DE Ferrara, R. Swerlick,
M. Vega-Ostertag, K. Casper,PL Meroni, EN Harris |
|
14.02 |
CONCORDANCE
AMONG APL ASSAYS IN ISCHEMIC STROKE: A SUBSET ANALYSIS OF THE
WARSS/APASS COLLABORATION
SR Levine, RL Brey, BC Tilley, JLT Thompson,
RL Sacco, PA Padilla,
E Du, JP
Mohr, &
The APASS Investigators, United States/Italy |
|
14.14 |
COMPLEMENT
C5 ACTIVATION MEDIATES ANTIPHOSPHOLIPID-INDUCED THROMBOSIS
SS Pierangeli,
ME Vega-Ostertag, G. Giradi,
X. Liu, JE
Salmon, United States
|
|
14.26 |
ANTIPHOSPHOLIPID-INDUCED
THROMBOSIS IS MEDIATED BY GPIIB/IIIA IN PLATELETS IN AN IN VIVO
MOUSE MODEL
M. Vega-Ostetag, FL Pianciola,
A. Liu, V. Henderson, EN Harris, SS Pierangeli, United States |
| |
|
14.38 |
EFFECT
OF BETA 2-GLYCOPROTEIN I NULL MUTATION ON REPRODUCTIVE OUTCOME
AND ANTIPHOSPHOLIPID ANTIBODY-MEDIATED PREGNANCY PATHOLOGY IN
MICE
T. Shi, S. Robertson, C. Roberts,
D. Bjeiring, k. pensa, y. Sheng, S.
Krilis, Australia |
|
14.50 |
ANTI-BETA2GLYCOPROTEIN
I ANTIBODIES POTENTIATE THE INHIBITORY EFFECTS OF BETA2GLYCOPROTEIN
I ON THE ACTIVATION OF FXI BY FIIa:
EFFECTS OF CLIPPED BETA2GLYCOPROTEIN I
Q. Yang, T. Shi, C. Bester, B. Giannakopoulos,
S. Krilis, Australia |
|
15.02 |
BETA2-GLYCOPROTEIN
I BINDS FXI BY ITS C-TERMINAL DOMAIN & INHIBITS ITS ACTIVATION
BY THROMBIN & FXIIa. PLASMIN CLEAVAGE OF B2-GPI ABOLISHES
ITS INHIBITION OF FXIIa ACTIVATION OF FXI
C. Bester, T. Shi,
GM Iverson, KA Cockerill, MD Linnik, P. Konecny, S. Krilis, Australia/United States |
|
15.14 |
BETA2-GLYCOPROTEIN
I BINDS FXI & INHIBITS ITS ACTIVATION BY THROMBIN AND FXIIa:
LOSS OF INHIBITION BY CLIPPED B2-GPI
C. Bester, T. Shi,
Q. Yang, B. Giannakopoulos, GM Iverson, JC Qi, KA Cockerill,
MD Linnik, P. Konecny, S. Krilis,
Australia/ United States |
|
15.26 |
ANTIPHOSPHOLIPID
ANTIBODIES DECREASE PLAQUE FORMATION IN ATHEROSCLEROSIS-PRONE
MICE
M. Monestier, D. Nicolo,
S-A Kang, United States |
|
15.38 |
ANTIPHOSPHOLIPID
SYNDROME NEPHROPATHY IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
WITH ANTIPHOSPHOLIPID ANTIBODIES
MG Tektonidou, F. Sotsiou,
L. Nakopoulou, PG Vlachoyiannopoulos,
HM Moutsopoulos, Greece |
|
15.50 |
RITUXIMAB
REDUCES ANTIPHOSPHOLIPID ANTIBODY TITERS & IMPROVES HYPERCOAGULABLE
STATE WITHOUT RECURRENT THROMBOSES: 2-YEARS FOLLOW UP
M. Yamazaki,
Y. Kawashima, A. Asakura, S. Nakao,
Japan |
| |
|
16.02 |
THE ANTIPHOSPHOLIPID
SYNDROME: IMMUNOLOGICAL AND CLINICAL ASPECTS
TM Reshetnyak, EN Alexandrova, IB Shtivelband, LV Kondrateva, AA Novikov, LA Kalashnikova, TA Lisitsyna, IE Shirokova, ZS Alekberova, EL Nassonov,
Russia
|
|
16.14 |
ANTIPHOSPHOLIPID
ANTIBODIES FOLLOWING VACCINATION WITH RECOMBINANT HEPATITIS
B VACCINE
B. Bozic, T.
Avcin, J. Martinuc, M. Kuhar, S. Cucnik, M. Zupancic, T. Kveder,
B. Rozman, Slovenia
|
|
16.26 |
COFFEE
BREAK
|
CHAIRPERSONS – Y. SHOENFELD, P.
VLACHOYIANNOPOULOS
|
16.56 |
HEAT SHOCK PROTEIN-60 REACTIVITY IS ASSOCIATED WITH ANTIPHOSPHOLIPID
ANTIBODIES IN VASCULITIS-RELATED AUTOIMMUNE DISEASES
P. Youinou, Y. Renaudinaeu, C. Dugué, J. Arvieux,
R. Perrault, S. Krilis, France/Australia
|
|
17.08 |
HEAT SHOCK PROTEIN REACTIVITY IS ASSOCIATED WITH ANTIPHOSPHOLIPID
ANTIBODIES IN VASCULITIS-RELATED AUTOIMMUNE DISEASE
P. Youinou, C.
Dugué, JC
Piette,
D. Mottier, L. Guillevin, C. Jamin, France
|
|
17.20 |
T LYMPHOCYTE SUBSETS IN PRIMARY ANTIPHOSPHOLIPID SYNDROME
PRJ
Ames, C.
Tommasino, G.
Fossati, LR
Lopez,
E. Matsuura, A. Margarita,
G. Scenna,
V. Brancaccio, Italy/United States/Japan/United
Kingdom
|
|
17.32 |
THE INFECTIOUS ETIOLOGY OF APS: NOVEL CROSS REACTIVE EPITOPES
ON YEASTS, BACTERIA AND VIRUSES
Y. Shoenfeld,
M. Blank, I. Krause, R. Cervera,
J. Font, M.
Torsten,
Israel
|
| 17.44 |
BOTH C4A & C4B NULL ALLELES ARE ASSOCIATED WITH APLIN
CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA
(ITP)
BL Myones,
KAB Marzan, JM Moulds,
United States
|
|
17.56 |
A STUDY OF ANTICARDIOLIPIN ANTIBODIES IN ECLAMPSIA
EG Dachlan, A. Sulistyono,
Indonesia
|
8.30-18.13 TUESDAY
NOVEMBER 16TH 2004
PREGNANCY AND
ANTIPHOSPHOLIPID ANTIBODIES
CHAIRPERSONS
– E. BENSON, RHWM DERKSON
|
8.30 |
GROWTH
AND FUNCTION OF THE NORMAL HUMAN PLACENTA
N. Gude, Australia
|
|
8.55 |
MATERNAL
HEMOSTASIS IN THE NORMAL PREGNANCY
B. Brenner, Israel
|
|
9.20 |
ANTIPHOSPHOLIPID
ANTIBODIES AND FETAL COMPROMISE
DW Branch, United States
|
|
9.40 |
TREATING
OF ANTIPHOSPHOLIPID SYNDROME IN PREGNANCY – A SYSTEMATIC REVIEW
OF THERAPEUTIC TRIALS
MN Lassere, M. Empson
Australia
|
|
10.00 |
IMMUNOLOGIC
MANIPULATION FOR THE THREATENED FOETUS
E. Benson, Australia
|
| 10.20 |
COFFEE
BREAK & POSTER VIEWING |
|
YOUNG INVESTIGATORS
CHAIRPERSONS –
C. ESMON, B. BRENNER, M. ZOUALI |
|
10.50
|
HUMAN MONOCLONAL
IGG ANTICARDIOLIPIN ANTIBODIES INDUCE NITRIC OXIDE SYNTHASE
EXPRESSION
J. Delgado Alves, BR Clapp, R. Stidwill, PP Chen,
AD Hingorani, M Singer,
DA Isenberg, United States
|
|
11.05 |
P38 MITOGEN
ACTIVATED PROTEIN KINASE IS INVOLVED IN UPREGULATION OF TISSUE
FACTOR IN ENDOTHELIAL CELLS BY ANTIPHOSPHOLIPID ANTIBODIES
ME Vega-Ostertag, V. Henderson,
EN Harris, SS Pierangeli,
United States
|
|
11.20 |
ANTIPHOSPHOLIPID
ANTIBODIES CAN REDUCE THE IN VITRO CLEAVAGE
OF DOMAIN V OF
BETA2-GLYCOPROTEIN I BY PLASMIN.
MJ Nash IJ Mackie H. Cohen SJ Machin, United
Kingdom
|
|
11.35 |
INDUCTION
OF ANTIPHOSPHOLIPID SYNDROME IN FACTOR V
LEIDEN MICE
A. Katzav, CG Pick,
M. Blank,Y. Shoenfeld,
J.Chapman
|
|
11.50 |
IDENTIFICATION
OF THE DOMAIN OF BETA2-GLYCOPROTEIN I INVOLVED IN BINDING TO
LRP
M. Van Lummel, RHWM Derksen,
BCH Lutters | |
14
- 18 November 2004
